BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla ACTM, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmod N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ; Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut 2021;70:1266-74. [PMID: 33046558 DOI: 10.1136/gutjnl-2019-319129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
4 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
5 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
6 Singh S, Picardo S, Seow CH. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin Gastroenterol Hepatol 2020;18:1367-80. [PMID: 31712084 DOI: 10.1016/j.cgh.2019.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
7 Rekawek P, Johnson S, Bigelow CA, Getrajdman C, Roy-McMahon C, Stoffels G, Dubinsky MC, Mella MT. Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease. Am J Obstet Gynecol MFM 2021;4:100518. [PMID: 34688951 DOI: 10.1016/j.ajogmf.2021.100518] [Reference Citation Analysis]
8 Yu A, Friedman S, Ananthakrishnan AN. Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1926-32. [PMID: 31895410 DOI: 10.1093/ibd/izz313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
9 De Felice KM, Kane S. Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol 2021;148:661-7. [PMID: 34489011 DOI: 10.1016/j.jaci.2021.07.005] [Reference Citation Analysis]
10 Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf 2020;43:147-61. [PMID: 31677004 DOI: 10.1007/s40264-019-00881-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
12 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kanis SL, van der Woude CJ. Proper Use of Inflammatory Bowel Disease Drugs during Pregnancy. Dig Dis 2016;34 Suppl 1:61-6. [PMID: 27548630 DOI: 10.1159/000447377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Eliesen GAM, van Drongelen J, van Hove H, Kooijman NI, van den Broek P, de Vries A, Roeleveld N, Russel FGM, Greupink R. Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta. Clin Pharmacol Ther 2020;108:99-106. [PMID: 32153014 DOI: 10.1002/cpt.1827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]